Working… Menu

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03697564
Recruitment Status : Not yet recruiting
First Posted : October 5, 2018
Last Update Posted : May 6, 2019
Stand Up To Cancer
Information provided by (Responsible Party):
Hitendra Patel, University of California, San Diego

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021